Biotechnology

GTG developing a genetic test in the fight against COVID-19

Finfeed Archived May 22, 2020

Genetic Technologies (ASX: GTG | NASDAQ: GENE) is fast-tracking development of a genetic test that will determine if people are at a high risk of contracting COVID-19.

Plenty of run left in Genetic Signatures

Finfeed Archived May 11, 2020

There has been continual strong news flow from the Genetic Signature Ltd (ASX: GSS), as it received CE-IVD registration for its SARS-CoV-2 Detection Kit, as well as notification from the Therapeutic Goods Administration (TGA) that its EasyScreenTM SARS-CoV-2 Detection Kit has been approved to be listed on the ARTG in Australia.

OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe

Next Investors Archived May 05, 2020

OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.

Proteomics awarded vital CE Mark registration for PromarkerD

Finfeed Archived Apr 16, 2020

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, has secured CE Mark registration for its PromarkerD Immunoassay kit as an IVD medical device (in vitro diagnostic).

Genetic Signatures builds on SARS technology

Finfeed Archived Mar 30, 2020

Shares in Genetic Signatures Limited (ASX: GSS) were up 50% at one stage on Monday morning as management announced that the company had supplemented its existing assays to specifically identify the 2019 novel strain of coronavirus (SARS-CoV-2), the virus that causes COVID-19.

Regeneus surges on back of Progenza patent news

Finfeed Archived Mar 23, 2020

The US Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for clinical-stage regenerative medicine company Regeneus Ltd's (ASX: RGS) lead stem cell platform technology Progenza.

Knee osteoarthritis treatment delivers Regeneus a A$1.6M milestone payment

Finfeed Archived Mar 20, 2020

Regeneus Ltd (ASX: RGS) today received a non-refundable milestone payment of ¥100M (approx. A$1.6M) from Kyocera Corporation (TYO:6971).

OncoSil granted FDA Breakthrough Device Designation

Finfeed Archived Mar 18, 2020

OncoSil Medical Ltd’s (ASX: OSL) OncoSil™ device has reached a significant milestone, receiving Breakthrough Device Designation by the US FDA for the treatment of unresectable locally advanced pancreatic cancer.

Regeneus inks agreement with high profile Japanese life sciences group

Finfeed Archived Mar 03, 2020

Clinical stage regenerative medicine company Regeneus Ltd (ASX:RGS) has signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in the life sciences industry.

OncoSil on verge of CE Mark approval

Finfeed Archived Feb 27, 2020

The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd (ASX:OSL) as it flags the finalisation of commercialisation plans for its OncoSil™ device ahead of CE marking early in 2020.

A listed Aussie company battling the Coronavirus

Finfeed Archived Feb 03, 2020

With the recent emergence in China of a new virulent strain of the Coronavirus, and the well-publicised impacts of that virus on human health, Zoono Group Limited (ASX:ZNO) has been inundated by public and shareholder enquiry concerning its products and their effectiveness in combatting the spread of the new virus.

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

Next Investors Archived Jan 30, 2020

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

Epichem contract to boost revenues at PharmAust

Finfeed Archived Jan 08, 2020

PharmAust Limited’s (ASX:PAA) wholly-owned subsidiary, Epichem Pty Ltd, has been awarded an extension to its current contract with Drugs for Neglected Diseases initiative.

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

Next Investors Archived Dec 19, 2019

One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).

Biotech stocks to watch in 2020

Finfeed Archived Dec 17, 2019

Finfeed runs the ruler over the biotech stocks to watch in 2020.

PharmAust Expands Site Recruitment for Phase II Pet Dog Cancer Trial

Finfeed Archived Dec 11, 2019

PharmAust Ltd (ASX:PAA), a clinical-stage oncology company that’s developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.

EverBlu sees 300% upside in BPH

Finfeed Archived Nov 29, 2019

The $3 million BPH Energy Ltd (ASX: BPH) has promising prospects with the ability to capitalise on the development of one or some of the assets held by Advent Energy.

Archer raises funds for Advanced Materials Business

Finfeed Archived Nov 29, 2019

Archer Materials Limited (ASX:AXE) has informed the market that it will close its Share Purchase Plan (SPP) on Friday, December 6, 2019 at 5 PM eastern daylight saving time.

< prev Page 2 of 5 next >